Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-mwx4w Total loading time: 0 Render date: 2024-07-04T01:35:00.174Z Has data issue: false hasContentIssue false

31 - Cholinergic therapy and Lewy body dementia

from Part three - Treatment issues

Published online by Cambridge University Press:  06 July 2010

Robert Perry
Affiliation:
Department of Neuropathology, Newcastle General Hospital
Ian McKeith
Affiliation:
University of Newcastle upon Tyne
Elaine Perry
Affiliation:
MRC Neurochemical Pathology Unit, Newcastle General Hospital
Get access

Summary

Summary

The concept of heterogeneity of Alzheimer's disease is based on molecular, neuropathological, clinical and neuropsychological features. An additional expression of possible heterogeneity has been revealed by the observation that patients affected by Alzheimer's disease differ in their response to pharmacologic interventions. This finding is stimulating a new experimental approach aimed at correlating neurochemical-neuropathological dysfunctions with the capability of selective drugs to improve specific ‘areas’ of cognition. The pharmacologic approach may thus serve as a tool to define specific subgroups of patients differentially responsive to a given therapy and, at the same time, to define new nosographic entities. Recent investigations evaluating the therapeutic potential of cholinesterase inhibitors have disclosed the existence of at least two subsets of demented patients defined as responders and nonresponders to the ‘cholinergic therapy’. The cluster of ‘responders’ to the cholinesterase inhibitors might include a significant number of subjects with a particularly severe dysfunction of the cholinergic system. The prominent vulnerability of the cholinergic system in the Lewy body dementia indirectly suggests that pharmacological treatments directly or indirectly enhancing cholinergic transmission might ameliorate some of the impaired cognitive functions.

The cholinergic deficit in degenerative dementia

Research on Alzheimer's disease (AD) over the past two decades has emphasized the dysfunctions of the basal forebrain cholinergic system. Drachman and Leavitt (1974) reported that anticholinergic drugs produce an acute state of cognitive impairment similar to the memory deficit observed in patients with AD. Accordingly, a direct relationship between the cholinergic system and AD was originally hypothesized.

Type
Chapter
Information
Dementia with Lewy Bodies
Clinical, Pathological, and Treatment Issues
, pp. 414 - 424
Publisher: Cambridge University Press
Print publication year: 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×